

IMPORTANT NOTICE UPDATE: Change to C1 Esterase Inhibitor Level and IgG Subclasses Assays

Effective: December 05, 2022

Dear Valued Client,

We are in the process of replacing our current instrumentation used in the quantitation of the IgG Subclasses and the C1 Esterase Inhibitor Levels. The new instrument is from the same manufacturer and uses the same turbidometric methodology, but there will be a change to the ordering test codes. Additionally, the reference range for the IgG Subclasses will remain unchanged. We will, however, be implementing a precision change for the C1 Esterase Inhibitor Level, so the reference range will be slightly different. Please see all changes outlined below.

| Test Name | Old Test Code | New Test Code |
|----------------|---------------|---------------|
| IgG Subclasses | IGGS | GSUB |

| Test Name | Old Test Code | Now Tost Codo | Old Reference Range (mg/dL) | New Reference Range (mg/dL) |
|--|---------------|---------------|--------------------------------|--------------------------------|
| C1 Esterase Inhibitor Level, Plasma | INHLP | CEILP | 20 – 37 | 20.0 – 36.8 |
| C1 Esterase Inhibitor Level, Serum | INHLS | CEILS | 20 – 37 | 20.0 – 36.8 |

Testing will be delayed and is expected to resume starting December 05, 2022, as we work to get this new platform up and running. We apologize for any inconvenience this may cause, and we thank you for your patience. If you have any questions, please contact our Client Service Team at 800.550.6227 or via email at ClinRefLabs@NJHealth.org.

Sincerely,

Steve Groshong, MD, PhD

St. J. Duch

Medical Director

Advanced Diagnostics Laboratories

National Jewish Health